Simon P. Hoerstrup
Directeur/Bestuurslid bij Geistlich Pharma AG
Profiel
Simon P.
Hoerstrup is the founder of Symetis SA (founded in 2001), InSphero AG (founded in 2009), and Xeltis AG (founded in 2006).
He is currently a Director at Geistlich Pharma AG.
Actieve functies van Simon P. Hoerstrup
Bedrijven | Functie | Begin |
---|---|---|
Geistlich Pharma AG
Geistlich Pharma AG Miscellaneous Commercial ServicesCommercial Services Geistlich Pharma AG researches, manufactures and provides pharmaceutical products, gelatine products, biomaterials and industrial glues. It offers Geistlich Bio-Oss and Geistlich Bio-Gide products. The firm specializes in biomaterials for the regeneration of bone, cartilage and tissue and develops, and manufactures medical devices. The company was founded in 1851 and is headquartered in Wolhusen, Switzerland. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Simon P. Hoerstrup
Bedrijven | Functie | Einde |
---|---|---|
InSphero AG
InSphero AG BiotechnologyHealth Technology InSphero AG supplies organotypic 3D microtissues for efficiency testing and toxicology in drug development. It offers 3D insight Islet, 3D InSight Tumor, Gravity TRAP ULA Plates, Cytotoxicity Assay Kit, 3D InSight in Vitro Toxixology services, imaging and automation. he company was founded by Jan Lichtenberg, Jens M. Kelm, Simon P. Hoerstrup and Wolfgang Moritz on March 26, 2009 and is headquartered in Schlieren, Switzerland. | Oprichter | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Oprichter | - |
SYMETIS SA | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Symetis SA
Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
Geistlich Pharma AG
Geistlich Pharma AG Miscellaneous Commercial ServicesCommercial Services Geistlich Pharma AG researches, manufactures and provides pharmaceutical products, gelatine products, biomaterials and industrial glues. It offers Geistlich Bio-Oss and Geistlich Bio-Gide products. The firm specializes in biomaterials for the regeneration of bone, cartilage and tissue and develops, and manufactures medical devices. The company was founded in 1851 and is headquartered in Wolhusen, Switzerland. | Commercial Services |
InSphero AG
InSphero AG BiotechnologyHealth Technology InSphero AG supplies organotypic 3D microtissues for efficiency testing and toxicology in drug development. It offers 3D insight Islet, 3D InSight Tumor, Gravity TRAP ULA Plates, Cytotoxicity Assay Kit, 3D InSight in Vitro Toxixology services, imaging and automation. he company was founded by Jan Lichtenberg, Jens M. Kelm, Simon P. Hoerstrup and Wolfgang Moritz on March 26, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Health Technology |